On March 25, 2022, Aimed Alliance and 31 other not-for-profit organizations and patient-advocacy groups sent a letter to Senators Shaheen and Capito and Representatives Thompson and McKinley supporting their introduction of Access to Prescription Digital Therapeutics Act of 2022 (H.R. 7051 and S.3791). Prescription Digital Therapies (PDTs) are prescription-only software that are regulated by the U.S. Food and Drug Administration (FDA). They deliver standardized, high-quality, and evidence-based therapeutic interventions to prevent, manage, or treat specific diseases and disorders. PDTs must demonstrate safety and effectiveness in randomized clinical trials. They require FDA premarket review and authorization, and they cannot be utilized unless they are prescribed by a licensed healthcare provider. This legislation would expand access to innovative therapeutics for patients with chronic diseases by ensuring Medicare has a mechanism for coverage and payment of PDTs and creating a new Medicaid payment category for PDTs. Read the letter here.
Last Updated on March 28, 2022 by Aimed Alliance
